All In Biotech

Drug Trial Radar · NCT00579956

A Randomized Double Blinded Comparison of Ceftazidime and Meropenem in Severe Melioidosis

Last checked: Nov 19, 2026Latest source record: Jun 4, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 750 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

750

Planned (sponsor's estimate)

Start

Dec 2007

Primary completion

Sep 2010

Study completion Sep 2010

Sponsor

Lead sponsor
University of OxfordAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Mahidol University; Wellcome Trust
First posted
Dec 24, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 15 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Melioidosis, an infection caused by the bacterium Burkholderia pseudomallei, is a major cause of community-acquired septicaemia in northeast Thailand. Common manifestations include cavitating pneumonia, hepatic and splenic abscesses, and soft tissue and joint infections. Despite improvements in diagnostic procedures and treatment, the mortality of severe melioidosis remains unacceptably high - approximately 35% with currently used antibiotics (ceftazidime or co-amoxiclav). There is clear evidence that antibiotics can affect mortality; the use of ceftazidime rather than previous regimens (doxycycline + chloramphenicol + co-trimoxazole) led to a 50% reduction in mortality from 80% to 35%. However, the mortality in the first 48 hours has not been altered by any treatment regimen. A key question is whether alternative antibiotics could improve early outcome. The hypothesis tested is that meropenem is superior to ceftazidime in terms of mortality for the treatment of melioidosis.

Conditions

  • Melioidosis

Interventions

  • MeropenemDrug

    Meropenem 1gm, diluted with 50ml normal saline solution IV every 8 hours for at least 10 days. The dose will be adjusted according to the creatinine clearance.

  • CeftazidimeDrug

    Ceftazidime 120mg/kg/day divided into 3 equal doses (maximum dose 2 gram/dose), diluted with 50ml normal saline solution IV every 8 hours for at least 10 days The dose will be adjusted according to the plasma creatinine level

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All cause mortalityTime frame: In hospital

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Udon Thani General Hospital

    Udon Thani, Thailand · Recruiting

  • Sappasithiprasong Hospital

    Ubonratchathani, Changwat Ubon Ratchathani, Thailand · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.